Sentences with phrase «standard chemotherapy in»

Addition of bevacizumab to standard chemotherapy in the neoadjuvant setting in patients with HER2 - negative metastatic breast cancer improves progression - free survival and the proportion of patients achieving pathological complete response.

Researchers observed the efficacy of the antibody alone or in combination with standard chemotherapy in mouse models of NHL, MM, and AML.

The current study examined the impact of CRS - 207 combined with standard chemotherapy in patients with advanced unresectable mesothelioma who were candidates for chemotherapy.

Merck's cancer immunotherapy Keytruda is one of the pharma giant's rising stars, especially in the wake of evidence that the therapy had a survival benefit over standard chemotherapy in advanced lung cancer patients.

That's not just because of Opdivo's failure — last month, Keytruda was shown to be better than standard chemotherapy in untreated advanced lung cancer patients with high levels of the PD - L1 protein, both stopping cancer progression and extending patients» lives.

Not exact matches

The targeted radiotherapy shrank tumors for 71 % of patients who had already failed standard chemotherapy, but these results came from a small trial that started with 30 patients and then added another 20 after positive data started rolling in.

The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumours in 50 % of patients suffering from early HER - 2 - negative breast cancer, the most common type of breast cancer.

In a head - to - head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous - non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

Importantly, these benefits were achieved with just one - third the rate of serious adverse events reported in the standard chemotherapy group.

«In the 20 years that I've been in practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and Drug Administration approval in March to treat such patients whose lung cancer progressed, despite standard chemotherapIn the 20 years that I've been in practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and Drug Administration approval in March to treat such patients whose lung cancer progressed, despite standard chemotherapin practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and Drug Administration approval in March to treat such patients whose lung cancer progressed, despite standard chemotherapin March to treat such patients whose lung cancer progressed, despite standard chemotherapy.

«Cdk2 cell cycle kinase seems to play a role in the ability of cancer cells to be more aggressive and resistant to standard chemotherapy,» Dr. Opyrchal said.

The combination of drugs appeared less toxic than standard chemotherapy, were relatively inexpensive and should be clinically evaluated, said Dwayne G. Stupack, PhD, the study's senior author and associate professor in the dDivision of Gynecologic Oncology at Moores Cancer Center.

Das explained that since the compounds they've developed make cancer cells more sensitive to attack, they also remove resistance to standard chemotherapy drugs — a serious problem in current therapies.

The researchers then used a combination of existing United States Food and Drug Administration - approved drugs to target autophagy and found ovarian cancer cells to be highly sensitive to these drugs in several different mouse cancer models — even among cells resistant to standard chemotherapy.

Dr. Dick says: «Our new findings add to that knowledge and we hope that we will soon have a new biomarker that will tell whether a patient will respond to standard chemotherapy, and then another to track patients in remission to identify those where treatment failed and the rare leukemia stem cells are coming back.

«In pancreatic, ovarian and liver cancers, we hope that by adding anti-cancer stem cell drugs to standard of care, we can control proliferating cells within the tumor that could otherwise help the tumor regenerate in the face of existing chemotherapies.&raquIn pancreatic, ovarian and liver cancers, we hope that by adding anti-cancer stem cell drugs to standard of care, we can control proliferating cells within the tumor that could otherwise help the tumor regenerate in the face of existing chemotherapies.&raquin the face of existing chemotherapies.»

Of the dogs stricken with osteosarcoma, 35 had the cancer in a leg which was subsequently amputated, followed by chemotherapy, which is the standard - of - care treatment; the dogs with elevated total cholesterol had a median survival time of 455 days, more than 200 days greater than the median survival time for dogs with normal cholesterol.

With that idea in mind, Karmali is leading an innovative Phase II clinical trial evaluating the effectiveness of combining the diabetes medication metformin with standard chemotherapy to treat patients with diffuse large B - cell lymphoma.

If it would be possible to identify tumours that have an aberrantly stabilised SOX9 protein, the drugs tested in this study could be used to prevent tumour spread in these patients and improve their response to standard chemotherapy.

TRINOVA - 1 was a randomized prospective phase III clinical trial that added trebananib or placebo to standard chemotherapy (weekly paclitaxel) among 919 women with recurrent ovarian cancer patient from 179 sites in 32 countries.

One hundred and one patients with metastatic uveal melanoma at 15 centers in the United States and Canada were randomized to receive either selumetinib or standard chemotherapy.

The activity - rest rhythm was recorded in 49 patients with advanced cancer while being given a standard chronomodulated chemotherapy cycle, which resulted in circadian disruption.

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

Dr Fiona Blackhall, a senior lecturer in The University of Manchester's Institute of Cancer Sciences and a consultant based at The Christie NHS Foundation Trust — both part of the Manchester Cancer Research Centre — said: «In order to introduce precision medicine, where each cancer patient receives treatment designed to target the genetic makeup of their individual cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.&raquin The University of Manchester's Institute of Cancer Sciences and a consultant based at The Christie NHS Foundation Trust — both part of the Manchester Cancer Research Centre — said: «In order to introduce precision medicine, where each cancer patient receives treatment designed to target the genetic makeup of their individual cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.&raquIn order to introduce precision medicine, where each cancer patient receives treatment designed to target the genetic makeup of their individual cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.»

In addition, TGen laboratory research also found that PPF increases the effectiveness of a standard - of - care chemotherapy drug called temozolomide (TMZ), and radiation, to treat glioblastoma.

It showed that those patients who received crizotinib did better with respect to improvement in symptoms and delay in growth of the cancer than those on standard chemotherapy.

In the dog clinical trial, all 30 dogs with non-Hodgkin's lymphoma treated with HCQ and the standard chemotherapy doxorubicin had clinical benefit, and nine had complete remission.

A phase I trial conducted by investigators at the Colorado State University Veterinary School in 30 dogs with non-Hodgkin's lymphoma with HCQ and the standard chemotherapy doxorubicin (DOX) showed a 100 percent clinical benefit rate.

The strong response to this new use of enzalutamide shows that it can provide a viable, less toxic alternative to chemotherapy in staving off the disease in men who aren't responding to standard first line hormonal treatments,» said Tomasz Beer, M.D., the lead author on the study and deputy director of the Knight Cancer Institute at OHSU.

For a median (midpoint) PFS of 6.4 months in patients treated with standard chemotherapy, the corresponding reduction of PFS in patient receiving EGFR TKI would be 1.9 months.

KEYNOTE - 024 investigated the efficacy of pembrolizumab compared to standard of care with platinum - based chemotherapy in untreated patients with advanced NSCLC and high PD - L1 expression (defined as expression in at least 50 % of tumour cells).

In elderly cancer patients like my father and aunt, who suffer from a variety of chronic health problems, physicians often modify standard treatment regimens — perhaps using two chemotherapy drugs instead of three or lowering standard dosages — in the hope that the revised treatment will work well enougIn elderly cancer patients like my father and aunt, who suffer from a variety of chronic health problems, physicians often modify standard treatment regimens — perhaps using two chemotherapy drugs instead of three or lowering standard dosages — in the hope that the revised treatment will work well enougin the hope that the revised treatment will work well enough.

In this study, researchers compared the effectiveness of the immunotherapy drug nivolumab (pronounced «nye VOL ue mab,» marketed at Opdivo), with standard - of - care chemotherapy in 541 patients with previously untreated or recurrent non-small cell lung cancer (NSCLC) that expressed PDL - 1 antibodieIn this study, researchers compared the effectiveness of the immunotherapy drug nivolumab (pronounced «nye VOL ue mab,» marketed at Opdivo), with standard - of - care chemotherapy in 541 patients with previously untreated or recurrent non-small cell lung cancer (NSCLC) that expressed PDL - 1 antibodiein 541 patients with previously untreated or recurrent non-small cell lung cancer (NSCLC) that expressed PDL - 1 antibodies.

The phase 3 trial described in the paper involved 347 patients with advanced or metastatic NSCLC who had already been treated with standard chemotherapy.

In mice with pancreatic cancer, three days of fasudil treatment prior to standard chemotherapy increased survival time by 47 per cent.

Commenting on the trial, Dr Alice Shaw, director of thoracic oncology at the Massachusetts General Hospital Cancer Centre in Boston, US, said: «This is the first randomised study to examine how a second generation ALK inhibitor compares to standard second line chemotherapy in ALK positive patients who failed the standard first line therapy, which currently is crizotinib.»

CPX - 351 delivers chemotherapy in a different way than standard chemotherapy.

In phase 3 trials for adults with high - risk, secondary AML, there was a statistically significant improvement in overall survival compared to patients who received a regimen using chemotherapy drugs delivered in the standard waIn phase 3 trials for adults with high - risk, secondary AML, there was a statistically significant improvement in overall survival compared to patients who received a regimen using chemotherapy drugs delivered in the standard wain overall survival compared to patients who received a regimen using chemotherapy drugs delivered in the standard wain the standard way.

Because AML is difficult to treat, standard treatment commonly involves multiple chemotherapy medicines that are given at a higher dose in order to kill the cancer cells.

But in the meantime, it would help if we could identify who won't benefit from standard treatment, so we can spare them the debilitating effects of chemotherapy and get them into clinical trials for experimental therapies that might be more effective.»

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression - free survival, researchers report at the ESMO 2014 Congress in Madrid.

«This is the first prospective and longitudinal study to characterize structural brain changes resulting from standard radiation and chemotherapy in patients with malignant brain tumors.

In a study presented today at a meeting of women's cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.

«The focus of chemotherapy and existing standard - of - care is on killing cancer cells but instead we took a completely different approach which changes the environment the cancer cells live in,» said Mick Bhatia, director and senior scientist with the McMaster Stem Cell and Cancer Research Institute, who led the group that performed the study.

In all instances, treatments involving the antibody — whether alone or in combination with chemotherapy — appeared to eradicate more cancer cells compared to standard carIn all instances, treatments involving the antibody — whether alone or in combination with chemotherapy — appeared to eradicate more cancer cells compared to standard carin combination with chemotherapy — appeared to eradicate more cancer cells compared to standard care.

When used alongside standard chemotherapy agents daunorubicin and cytarabine in a treatment - resistant AML model, 99.7 percent of cancer cells were killed.

The 11 evaluable patients enrolled in the brain cancer safety trial received three infusions of vitamin C a week for 2 months followed by two infusions per week for 7 months while receiving standard care radiation and chemotherapy.

«PF - 06747143 could potentially be used as a standalone therapy for patients who are not candidates for standard care or used in combination with chemotherapy,» noted Dr. Pernasetti.

Albeit still limited in efficacy, angiogenesis - inhibiting drugs have become part of standard tumor therapy supporting the efficacy of established chemotherapies.

(In clinical trials, HER2 - positive patients receiving Herceptin and standard combination chemotherapy had a 52 percent decrease in disease recurrence compared with patients treated with chemotherapy aloneIn clinical trials, HER2 - positive patients receiving Herceptin and standard combination chemotherapy had a 52 percent decrease in disease recurrence compared with patients treated with chemotherapy alonein disease recurrence compared with patients treated with chemotherapy alone.)